Cargando…
Growth hormone insensitivity: Mexican case report
Herein, we present a 14-year-old patient with short stature (134 cm) referred from Paediatrics to our department for complementary evaluation since growth hormone (GH) treatment failed to show any improvement. He was born premature and small for gestational age. Genital examination classified the pa...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5682564/ https://www.ncbi.nlm.nih.gov/pubmed/29147569 http://dx.doi.org/10.1530/EDM-17-0126 |
_version_ | 1783278120360476672 |
---|---|
author | Castilla-Cortazar, I De Ita, J R Aguirre, G A García–Magariño, M Martín-Estal, I Lara-Diaz, V J Elizondo, M I |
author_facet | Castilla-Cortazar, I De Ita, J R Aguirre, G A García–Magariño, M Martín-Estal, I Lara-Diaz, V J Elizondo, M I |
author_sort | Castilla-Cortazar, I |
collection | PubMed |
description | Herein, we present a 14-year-old patient with short stature (134 cm) referred from Paediatrics to our department for complementary evaluation since growth hormone (GH) treatment failed to show any improvement. He was born premature and small for gestational age. Genital examination classified the patient as Tanner I–II with small penis and testicular size for his age. Biochemical analyses revealed normal GH levels with low serum insulin-like growth factor-1 (IGF-1). Molecular diagnosis confirmed several mutations in IGF1R and IGFALS, and so he was diagnosed with Laron Syndrome or GH insensibility and treated with IGF-1 substitutive therapy. LEARNING POINTS: Evaluation of the GH/IGF-1 axis when short stature does not respond to conservative treatment must be included in the ordinary practice. Laron Syndrome real incidence should be calculated once undiagnosed cases arise, as treatment, due to lack of market, is unaffordable. Even when adulthood is reached, and no longitudinal growth can be achieved, still IGF-1 treatment in Laron Syndrome patients should be pursued as metabolic and protective derangements could arise. |
format | Online Article Text |
id | pubmed-5682564 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Bioscientifica Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-56825642017-11-16 Growth hormone insensitivity: Mexican case report Castilla-Cortazar, I De Ita, J R Aguirre, G A García–Magariño, M Martín-Estal, I Lara-Diaz, V J Elizondo, M I Endocrinol Diabetes Metab Case Rep Insight into Disease Pathogenesis or Mechanism of Therapy Herein, we present a 14-year-old patient with short stature (134 cm) referred from Paediatrics to our department for complementary evaluation since growth hormone (GH) treatment failed to show any improvement. He was born premature and small for gestational age. Genital examination classified the patient as Tanner I–II with small penis and testicular size for his age. Biochemical analyses revealed normal GH levels with low serum insulin-like growth factor-1 (IGF-1). Molecular diagnosis confirmed several mutations in IGF1R and IGFALS, and so he was diagnosed with Laron Syndrome or GH insensibility and treated with IGF-1 substitutive therapy. LEARNING POINTS: Evaluation of the GH/IGF-1 axis when short stature does not respond to conservative treatment must be included in the ordinary practice. Laron Syndrome real incidence should be calculated once undiagnosed cases arise, as treatment, due to lack of market, is unaffordable. Even when adulthood is reached, and no longitudinal growth can be achieved, still IGF-1 treatment in Laron Syndrome patients should be pursued as metabolic and protective derangements could arise. Bioscientifica Ltd 2017-11-09 /pmc/articles/PMC5682564/ /pubmed/29147569 http://dx.doi.org/10.1530/EDM-17-0126 Text en © 2017 The authors http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en_GB This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en_GB) . |
spellingShingle | Insight into Disease Pathogenesis or Mechanism of Therapy Castilla-Cortazar, I De Ita, J R Aguirre, G A García–Magariño, M Martín-Estal, I Lara-Diaz, V J Elizondo, M I Growth hormone insensitivity: Mexican case report |
title | Growth hormone insensitivity: Mexican case report |
title_full | Growth hormone insensitivity: Mexican case report |
title_fullStr | Growth hormone insensitivity: Mexican case report |
title_full_unstemmed | Growth hormone insensitivity: Mexican case report |
title_short | Growth hormone insensitivity: Mexican case report |
title_sort | growth hormone insensitivity: mexican case report |
topic | Insight into Disease Pathogenesis or Mechanism of Therapy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5682564/ https://www.ncbi.nlm.nih.gov/pubmed/29147569 http://dx.doi.org/10.1530/EDM-17-0126 |
work_keys_str_mv | AT castillacortazari growthhormoneinsensitivitymexicancasereport AT deitajr growthhormoneinsensitivitymexicancasereport AT aguirrega growthhormoneinsensitivitymexicancasereport AT garciamagarinom growthhormoneinsensitivitymexicancasereport AT martinestali growthhormoneinsensitivitymexicancasereport AT laradiazvj growthhormoneinsensitivitymexicancasereport AT elizondomi growthhormoneinsensitivitymexicancasereport |